A5069875702- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Virus-based gene therapy research
- Single-cell and spatial transcriptomics
- Pneumonia and Respiratory Infections
- CRISPR and Genetic Engineering
- Tuberculosis Research and Epidemiology
- Childhood Cancer Survivors' Quality of Life
- Respiratory viral infections research
- Biosimilars and Bioanalytical Methods
- Pluripotent Stem Cells Research
- Otitis Media and Relapsing Polychondritis
- Hematopoietic Stem Cell Transplantation
- Neuropeptides and Animal Physiology
- Cancer, Stress, Anesthesia, and Immune Response
- Diagnosis and treatment of tuberculosis
- Cell Image Analysis Techniques
- Immune Response and Inflammation
- Lymphoma Diagnosis and Treatment
- Pneumocystis jirovecii pneumonia detection and treatment
- Integrated Circuits and Semiconductor Failure Analysis
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Kawasaki Disease and Coronary Complications
- Autoimmune and Inflammatory Disorders Research
Hospital Universitario Virgen del Rocío
2010-2025
Instituto de Biomedicina de Sevilla
2012-2024
Universidad de Sevilla
2012-2024
Centro de Investigación Biomédica en Red de Cáncer
2018-2021
Centro de Investigación Biomédica en Red
2021
Consejo Superior de Investigaciones Científicas
2021
Instituto de Salud Carlos III
2016
<h3>Background</h3> Immunodysregulation polyendocrinopathy enteropathy x-linked (IPEX) syndrome is a monogenic autoimmune disease caused by <i>FOXP3</i> mutations. Because it rare disease, the natural history and response to treatments, including allogeneic hematopoietic stem cell transplantation (HSCT) immunosuppression (IS), have not been thoroughly examined. <h3>Objective</h3> This analysis sought evaluate onset, progression, long-term outcome of 2 main treatments in IPEX survivors....
Purpose CAR-T cell therapy has proven to be a disruptive treatment in the hematology field, however, less than 50% of patients maintain long-term response and early predictors outcome are still inconsistently defined. Here, we aimed optimize detection CD19 cells blood identify phenotypic features as biomarkers associated with toxicity outcomes. Experimental design In this study, monitoring by flow cytometry digital PCR (dPCR), immunophenotypic characterization circulating from 48 treated...
Introduction Loss of B-cell aplasia (BCA) is a well-known marker functional loss CD19 CAR-T. Most relapses and BCA occur in the first months after CAR-T infusion. In addition, high tumor burden (HTB) has shown to have strong impact on relapse, especially CD19-negative. However, little known about late or relationship between pre-infusion patients infused with tisagenlecleucel for relapsed/refractory acute lymphoblastic leukemia. Therefore, optimal management yet be defined. Methods We...
Summary Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use blinatumomab, or both. The complete remission (CR) rate a heavily pretreated population overt relapse was 47·6%. At earlier stages (first/second CR), both antibodies represented useful tool reduce minimal residual disease, and/or avoid further toxic until stem cell...
The Wiskott-Aldrich syndrome (WAS) is an X-linked primary immunodeficiency caused by mutations in the WAS gene and characterized severe thrombocytopenia. Although role of WASp terminally differentiated lymphocytes myeloid cells well characterized, its early hematopoietic differentiation platelets (Plts) biology poorly understood. In present manuscript, we have used zinc finger nucleases targeted to locus for development two isogenic knockout (WASKO) human embryonic stem cell lines (hESCs)....
Robust and applicable risk-stratifying genetic factors at diagnosis in pediatric T-cell acute lymphoblastic leukemia (T-ALL) are still lacking, most protocols rely on measurable residual disease (MRD) assessment. In our study, we aimed to analyze the impact of NOTCH1, FBXW7, PTEN , RAS mutations, levels assessed by flow cytometry (FCM-MRD) other reported risk a Spanish cohort T-ALL patients. We included 199 patients treated with SEHOP PETHEMA consecutive from 1998 2019. observed better...
We report on the emergence and clinical relevance of an unusual BCR-ABL1 kinase domain mutational status in a 2-year-old female with p210-BCR-ABL Philadelphia chromosome-positive acute lymphoblastic leukaemia. detected three clones determined by presence E255V, D276G F317L mutations. point out usefulness searching for mutated populations that survive tyrosine-kinase inhibitor therapy role their clonal selection over time relation to therapeutic intervention.
<title>Abstract</title> Hematological toxicity is the most common long-term adverse event after CAR T-cell therapy. Severe cytopenias not resolving over time may result in life-threatening infection or bleeding and best clinical practice to treat this persisting CAR-T well established. Eleven heavily pretreated patients with B-ALL prolonged cytopenia therapy were successfully treated an allogeneic CD34<sup>+</sup> hematopoietic stem cell (HSC) boost. The median from infusion donor HSC boost...
Abstract B-cell Acute Lymphoblastic Leukemia is the most prevalent form of childhood cancer, with approximately 15% patients undergoing relapse after initial treatment. Further advancements depend on novel therapies and more precise risk stratification criteria. In context computational flow cytometry machine learning, this paper aims to explore potential prognostic value data at diagnosis, a relatively unexplored direction for prediction in disease. To end, we collected dataset 252 from...
Topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research Background: CAR-T cell therapy has proven to be a disruptive treatment in the hematology field. Tisagenlecleucel Axicabtagene ciloleucel showed impressive efficacy relapsed/refractory B-cell lymphoma; however, less than 50% of patients maintain long-term response predictors outcome are inconsistently defined. Tisa-cel Axi-cel kinetics have been poorly investigated real life settings so it...
Abstract Although children and adolescents with acute lymphoblastic leukaemia (ALL) have high survival rates, approximately 15-20% of patients relapse. Risk relapse is routinely estimated at diagnosis by biological factors, including flow cytometry data. This high-dimensional data typically manually assessed projecting it onto a subset biomarkers. Cell density “empty spaces” in 2D projections the data, i.e. regions devoid cells, are then used for qualitative assessment. Here, we use...